Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $88.27 USD
Change Today +0.195 / 0.22%
Volume 69.8K
ICUI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

951 Calle Amanecer

San Clemente, CA 92673

United States

Phone: 949-366-2183

Fax: 949-366-8368

ICU Medical, Inc. engages in the development, manufacture, and sale of medical devices used in infusion therapy, oncology and critical care applications. The company’s products improve patient outcomes by helping to prevent bloodstream infections through the use of hemodynamic monitoring for critically ill patients and protecting healthcare workers from exposure to infectious diseases or hazardous drugs. The company’s complete product line includes needlefree infusion connectors, custom infusion systems, catheters and hemodynamic monitoring systems and closed system transfer devices and automated compounders for handling hazardous drugs. Its products are used in hospitals and alternate medical sites in approximately 55 countries throughout the world. Products Infusion Therapy I.V. therapy lines, used in hospitals and ambulatory clinics, consist of a tube running from a bottle or plastic bag containing an I.V. solution to a catheter inserted in a patient’s vein. The tube typically has various injection ports or Y-sites (conventionally, entry tubes covered by rubber caps) to which a secondary I.V. line can be connected to permit constant intravenous administration of medications, fluids and nutrients, and to allow instantaneous intravenous administration of emergency medication. Clave Needlefree I.V. Technology The Clave consists of a cylindrical housing, which contains a pre-slit silicone compression seal and an internal blunt cannula. As the luer tip enters the Clave housing, it depresses the silicone seal back into the housing and slides over the blunt cannula, which penetrates through the pre-slit silicone. Fluid channels in the blunt cannula create a continuous fluid pathway from the I.V. line, through the Clave into the primary I.V. line and into the catheter. The luer tip creates a tight seal against the top of the silicone thereby preventing contaminants from entering the fluid pathway or fluid from escaping the connection. The Y-Clave is designed to be integrated directly into primary and secondary I.V. sets, thus eliminating the need for special adapters, pre-slit injection ports, or metal needles when making piggyback I.V. connections. The Y-Clave does not replace Clave products used in non-piggyback connections. Both the original Clave and the Y-Clave are marketed to I.V. set manufacturers, such as Hospira, Inc. (Hospira), to build directly into their I.V. sets or used by the company in its custom infusion sets. The MicroClave is smaller than the standard Clave but is functionally similar. The MicroClave has a feature where upon disconnection of an I.V. administration set or syringe, there is a neutral displacement of fluid. This allows clinicians to utilize known protocols without the risk of device failure and a saline flush regimen which reduces cost and exposure to the drug Heparin, an anti-clotting agent. The MicroClave is intended for use on all peripheral and central catheters, which allows it to be used throughout the hospital and reduces line items that the hospital may need to carry and the educational burden of having multiple devices. The MicroClave is being marketed as an extension of the Clave product line for use where the infection control, neutral displacement and saline flush features are advantageous. The NanoClave is smaller than the MicroClave and is designed for use on neonatal and pediatric patients. The device has a clear housing and incorporates Clave technology into a smaller connector, allowing clinicians to flush the connector clear of blood with minimal flush volumes. Neutron The Neutron catheter patency device also features Clave technology, but includes a bi-directional silicone valve that helps prevent blood reflux into a catheter to minimize the incidence of occlusion, or blocking of the catheter due to a blood clot. The Neutron was specifically designed to be used on patients receiving longer indwelling central I.V. lines. Custom Infusion Sets The company has developed software systems and manufacturing processes known as SetMaker and iFactory that permit it to design a custom infusion set to a hospital’s or clinician’s exact specifications

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICUI:US $88.27 USD +0.195

ICUI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $17.10 USD +0.25
Cyberonics Inc $62.89 USD -0.30
NxStage Medical Inc $19.40 USD +0.04
Orthofix International NV $36.46 USD +0.10
Wright Medical Group Inc $26.26 USD -0.03
View Industry Companies
 

Industry Analysis

ICUI

Industry Average

Valuation ICUI Industry Range
Price/Earnings 52.4x
Price/Sales 4.4x
Price/Book 2.7x
Price/Cash Flow 52.4x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICU MEDICAL INC, please visit www.icumed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.